Isolation of tumour antigen specific scFv's using a chimeric antigen receptor bicistronic retroviral vector in a mammalian screening protocol.
AffiliationUniversity of Manchester, CIMML, Manchester, United Kingdom
MetadataShow full item record
AbstractThe clinical potential of chimeric antigen receptors in adoptive cellular therapy is beginning to be realised with several recent clinical trials targeting CD19 showing promising results in advanced B cell malignancies. This increased efficacy corresponds with improved engineering of the chimeric receptors with the latest generation receptors eliciting greater signalling and proliferation potential. However, the antigen binding scFv domain of the receptors is critical in determining the activity of the chimeric receptor expressing T cells; as this determines specificity and affinity to the tumour antigen. In this study, we describe a mammalian T-cell line screening protocol employing a 2A-based bicistronic retroviral vector to isolate functional scFv's. This approach involves expression of the scFv library in a CAR, and is based on selection of clones capable of stimulating CD69 upregulation in a T cell line and has a number of advantages over previously described methods in that the use of a 2A-cassette ensures the exclusion of non-expressing scFv's and the screening using a chimeric receptor in a mammalian T-cell line ensures selection in the optimum context for therapeutic use. Proof of principle experiments show that the protocol was capable of a 105-fold enrichment of positive clones following three rounds of selection. Furthermore, an antigen specific clone was successfully isolated from a partially enriched scFv library confirming the strength of the protocol. This approach has the potential to identify novel scFv's of use in adoptive T cell therapy and, potentially, wider antibody-based applications.
CitationIsolation of tumour antigen specific scFv's using a chimeric antigen receptor bicistronic retroviral vector in a mammalian screening protocol. 2013: Hum Gene Ther Methods
JournalHuman Gene Therapy Methods
- T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
- Authors: Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L, Moghimi SM
- Issue date: 2014 Jan
- One-step expression and purification of single-chain variable antibody fragment using an improved hexahistidine tag phagemid vector.
- Authors: Zhao Q, Chan YW, Lee SS, Cheung WT
- Issue date: 2009 Dec
- Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
- Authors: Ma Q, Gomes EM, Lo AS, Junghans RP
- Issue date: 2014 Feb
- Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.
- Authors: Tassev DV, Cheng M, Cheung NK
- Issue date: 2012 Feb
- Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
- Authors: Smith EL, Staehr M, Masakayan R, Tatake IJ, Purdon TJ, Wang X, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Riviere I, Liu C, Brentjens RJ
- Issue date: 2018 Jun 6